Shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) traded down 3.8% during trading on Thursday . The company traded as low as $16.62 and last traded at $16.81, with a volume of 61,639 shares. The stock had previously closed at $17.47.

A number of analysts have commented on the company. Zacks Investment Research raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. SunTrust Banks Inc. assumed coverage on La Jolla Pharmaceutical in a report on Wednesday, June 22nd. They issued a “buy” rating and a $30.00 target price for the company. Jefferies Group reissued a “buy” rating on shares of La Jolla Pharmaceutical in a report on Wednesday, June 8th. Finally, Lake Street Capital assumed coverage on La Jolla Pharmaceutical in a report on Tuesday, May 24th. They issued a “buy” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $39.50.

The stock’s market cap is $309.95 million. The stock has a 50-day moving average price of $16.70 and a 200-day moving average price of $17.49.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.22. Analysts predict that La Jolla Pharmaceutical Co. will post ($3.99) earnings per share for the current year.

A hedge fund recently raised its stake in La Jolla Pharmaceutical stock. P.A.W. Capital Corp increased its position in La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical makes up approximately 1.5% of P.A.W. Capital Corp’s investment portfolio, making the stock its 28th largest position. P.A.W. Capital Corp owned approximately 0.28% of La Jolla Pharmaceutical worth $1,361,000 as of its most recent SEC filing.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.